- Biomarker developer Oxford BioDynamics booked a first-half loss after rising revenue was more than offset by expenses, including staff and R&D costs.

Pre-tax losses for the six months through March amounted to £1.6m, compared to losses of £1.4m on-year.

Revenue grew to £0.6m, from £0.5m on-year.

'We have made further strong operational and commercial progress in the first half of the year,' chief executive Christian Hoyer Millar said.

'Our EpiSwitch technology platform has been adopted by prestigious clinical trials in the US and UK; we have enhanced the senior leadership team and Board to drive the next phase of growth; and have entered into promising new collaboration agreements.'

'We were also delighted to be awarded the prestigious Queen's Award for Enterprise: Innovation, a great recognition of the value our EpiSwitch platform has generated to date.'

At 8:30am: [LON:OBD] Oxford Biodynamics Plc share price was -4p at 158.5p

Story provided by